Table 2.

Observational studies of aspirin use and risk of hepatocellular carcinoma (HCC)

STUDY (AUTHOR, YEAR)	REGION	STUDY DESIGN	HCC CASES (N)	ASPIRIN USERS (N)	TOTAL (N)	HCC RISK (OR, RR, HR; 95% CI)
SIMON, 2020	Sweden	Retrospective Cohort	1,612	14,205	50,275	0.69 (0.62–0.76)
DU, 2019	China	Retrospective Cohort	41	59	264	0.16 (0.04–0.71)
LEE, T, 2019	Korea	Retrospective Cohort	697	2,123	10, 615	0.70 (0.58–0.86)
TSOI, 2019	Hong Kong	Retrospective Cohort	9,370	204,170	612,509	0.49 (0.45–0.53)
HWANG, 2018	Korea	Prospective Cohort	2,336	64,782	460,755	0.87 (0.77–0.98)
SIMON, 2018	USA	Prospective Cohort	108	58,855	133,371	0.51 (0.34–0.77)
LIN, 2018	Taiwan	Retrospective Cohort	110	3,576	18,243	0.67 (0.42–1.08)
TSENG, 2018	Taiwan	Retrospective Cohort	1,750	23,112	43,800	0.83 (0.69–0.99)
LEE, M, 2017	Korea	Retrospective Cohort*	63	343	14,392	0.34 (0.15–0.77)
LEE, T, 2017	Taiwan	Retrospective Cohort	NR	5,602	18,080	0.70 (0.37–1.36)
KIM, 2017	Korea	Case Control	229	390	1,374	0.34 (0.15–0.78)
YANG, 2016	UK	Case Control	1,195	1,670	5,835	1.11 (0.86–1.44)
PETRICK, 2015	USA	Prospective Cohort	679	477,470	1,084,133	0.68 (0.57–0.81)
SAHASRABUDDHE, 2012	USA	Prospective Cohort	250	89,585	300,504	0.51 (0.35–0.75)
CHIU, 2011	Taiwan	Case Control	1,166	162	2,332	1.0 (0.73–1.38)
FRIIS, 2003	Danish	Retrospective Cohort	21	29,470	29,470	1.0 (0.60–1.50)
COOGAN, 2000	USA	Case Control	51	491	7,101	0.90 (0.30–2.90)

Abbreviatons: N, number; HCC, hepatocellular carcinoma; OR, odds ratio; RR, relative risk; HR, hazard ratio; CI, confidence interval

^*Estimates provided are from the propensity score-matched cohort